2122 Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance therapy or mFOLFOX plus cetuximab in patients with metastatic colorectal cancer: The MACRO-2 trial. (September 2015)

• Record Type: Journal Article
• Authors: Aranda, E.; García-Alfonso, P.; Benavides, M.; Sanchez-Ruiz, A.; Guillen-Ponce, C.; Safont, M.J.; Alcaide, J.; Gomez, A.; Lopez, R.; Manzano, J.L.; Mendez-Urena, M.; Lopez, C.; García-Paredes, B.; Grávalos, C.; García-García, T.; Falco, E.; Martin-Valades, J.I.; Gonzalez-Flores, E.; Navalon, M.; Diaz-Rubio, E.
• Is Part Of: European journal of cancer. Volume 51:(2015)Supplement 3
• Page Start: S371
• Page End: S372
• Publication Date: 2015-09
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/S0959-8049(16)31044-9
• Languages: English
• ISSNs: 0959-8049